Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $40
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $30 to $40.
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $30 to $40.